Journal Article
. 2008 Jun;5(3).
doi: 10.1177/1740774508091815.

Bayesian adaptive design for targeted therapy development in lung cancer--a step toward personalized medicine

Xian Zhou 1 Suyu Liu  Edward S Kim  Roy S Herbst  J Jack Lee  
  • PMID: 18559407
  •     25 References
  •     59 citations


Background: With the advancement in biomedicine, many biologically targeted therapies have been developed. These targeted agents, however, may not work for everyone. Biomarker profiles can be used to identify effective targeted therapies. Our goals are to characterize the molecular signature of individual tumors, offer the best-fit targeted therapies to patients in a study, and identify promising agents for future development.

Methods: We propose an outcome-based adaptive randomization trial design for patients with advanced stage non-small cell lung cancer. All patients have baseline biopsy samples taken for biomarker assessment prior to randomization to treatments. The primary endpoint of this study is the disease control rate at 8 weeks after randomization. The Bayesian probit model is used to characterize the disease control rate. Patients are adaptively randomized to one of four treatments with the randomization rate based on the updated disease control rate from the accumulated data in the trial. For each biomarker profile, high-performing treatments have higher randomization rates, and vice versa. An early stopping rule is implemented to suspend low-performing treatments from randomization.

Results: Based on extensive simulation studies, with a total of 200 evaluable patients, our trial has desirable operating characteristics to: (1) identify effective agents with a high probability; (2) suspend ineffective agents; and (3) treat more patients with effective agents that correspond to their biomarker profiles. Our trial design continues to update and refine the estimates as the trial progresses.

Limitations: This biomarker-based trial requires biopsible tumors and a two-week turn around time for biomarker profiling before randomization. Additionally, in order to learn from the interim data and adjust the randomization rate accordingly, the outcome-based adaptive randomization design is applicable only for trials when the endpoint can be assessed in a relative short period of time.

Conclusion: Bayesian adaptive randomization trial design is a smart, novel, and ethical design. In conjunction with an early stopping rule, it can be used to efficiently identify effective agents, eliminate ineffective ones, and match effective treatments with patients' biomarker profiles. The proposed design is suitable for the development of targeted therapies and provides a rational design for personalized medicine.

Genomic and proteomic approaches for studying human cancer: prospects for true patient-tailored therapy.
Kristen M Carr, Kevin Rosenblatt, Emanuel F Petricoin, Lance A Liotta.
Hum Genomics, 2004 Dec 17; 1(2). PMID: 15601541    Free PMC article.
Introduction to Bayesian methods II: fundamental concepts.
Thomas A Louis.
Clin Trials, 2005 Nov 12; 2(4). PMID: 16281427
Covariate-adjusted adaptive randomization in a sarcoma trial with multi-stage treatments.
Peter F Thall, J Kyle Wathen.
Stat Med, 2005 Apr 05; 24(13). PMID: 15806621
Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trials.
Primo N Lara, Mary W Redman, +5 authors, Southwest Oncology Group.
J Clin Oncol, 2008 Jan 19; 26(3). PMID: 18202421
Adaptive designs for binary treatment responses in phase III clinical trials: controversies and progress.
A Biswas.
Stat Methods Med Res, 2001 Nov 08; 10(5). PMID: 11697227
Adaptive trial design.
Donald A Berry.
Clin Adv Hematol Oncol, 2007 Aug 08; 5(7). PMID: 17679925
Randomized play-the-winner clinical trials: review and recommendations.
W F Rosenberger.
Control Clin Trials, 1999 Aug 10; 20(4). PMID: 10440560
Ethics, data-dependent designs, and the strategy of clinical trials: time to start learning-as-we-go?
C R Palmer.
Stat Methods Med Res, 2002 Oct 03; 11(5). PMID: 12357585
Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development.
John W Park, Robert S Kerbel, +7 authors, Dennis J Slamon.
Clin Cancer Res, 2004 Jun 03; 10(11). PMID: 15173098
Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.
Nasser Hanna, Frances A Shepherd, +17 authors, Paul A Bunn.
J Clin Oncol, 2004 May 01; 22(9). PMID: 15117980
Highly Cited.
The method of minimization for allocation to clinical trials. a review.
Neil W Scott, Gladys C McPherson, Craig R Ramsay, Marion K Campbell.
Control Clin Trials, 2002 Dec 31; 23(6). PMID: 12505244
Highly Cited. Review.
Development of the novel biologically targeted anticancer agent gefitinib: determining the optimum dose for clinical efficacy.
Michael Wolf, Helen Swaisland, Steven Averbuch.
Clin Cancer Res, 2004 Jul 23; 10(14). PMID: 15269131
Clinical trials design and treatment tailoring: general principles applied to breast cancer research.
P Therasse, S Carbonnelle, J Bogaerts.
Crit Rev Oncol Hematol, 2006 Jan 25; 59(2). PMID: 16431124
Randomized phase II designs in cancer clinical trials: current status and future directions.
J Jack Lee, Lei Feng.
J Clin Oncol, 2005 Jul 05; 23(19). PMID: 15994154
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
F V Fossella, R DeVore, +14 authors, L Hammershaimb.
J Clin Oncol, 2000 Jun 16; 18(12). PMID: 10856094
Highly Cited.
On the efficiency of targeted clinical trials.
A Maitournam, R Simon.
Stat Med, 2004 Nov 20; 24(3). PMID: 15551403
Drug development in oncology: classical cytotoxics and molecularly targeted agents.
Shivaani Kummar, Martin Gutierrez, James H Doroshow, Anthony J Murgo.
Br J Clin Pharmacol, 2006 Jul 18; 62(1). PMID: 16842375    Free PMC article.
Bayesian clinical trials.
Donald A Berry.
Nat Rev Drug Discov, 2006 Feb 18; 5(1). PMID: 16485344
Highly Cited. Review.
Ethical issues in oncology biostatistics.
Peter F Thall.
Stat Methods Med Res, 2002 Oct 03; 11(5). PMID: 12357588
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
S J Pocock, R Simon.
Biometrics, 1975 Mar 01; 31(1). PMID: 1100130
Highly Cited.
Development of molecular targeted anticancer agents: successes, failures and future directions.
Eric X Chen, Lillian L Siu.
Curr Pharm Des, 2005 Jan 11; 11(2). PMID: 15638762
Unique issues in the development of "targeted" antineoplastic pharmaceutical agents.
Maurie Markman.
Curr Oncol Rep, 2005 Jun 11; 7(4). PMID: 15946580
Evaluating the efficiency of targeted designs for randomized clinical trials.
Richard Simon, Aboubakar Maitournam.
Clin Cancer Res, 2004 Oct 27; 10(20). PMID: 15501951
Introduction to Bayesian methods III: use and interpretation of Bayesian tools in design and analysis.
Donald A Berry.
Clin Trials, 2005 Nov 12; 2(4). PMID: 16281428
Introduction to Bayesian methods I: measuring the strength of evidence.
Steven N Goodman.
Clin Trials, 2005 Nov 12; 2(4). PMID: 16281426
Bayesian clinical trials at the University of Texas M. D. Anderson Cancer Center.
Swati Biswas, Diane D Liu, J Jack Lee, Donald A Berry.
Clin Trials, 2009 Jun 17; 6(3). PMID: 19528130    Free PMC article.
Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges.
Sumithra J Mandrekar, Daniel J Sargent.
J Clin Oncol, 2009 Jul 15; 27(24). PMID: 19597023    Free PMC article.
Highly Cited.
Genomic advances and their impact on clinical trial design.
Sumithra J Mandrekar, Daniel J Sargent.
Genome Med, 2009 Jul 30; 1(7). PMID: 19638184    Free PMC article.
Predictive biomarker validation in practice: lessons from real trials.
Sumithra J Mandrekar, Daniel J Sargent.
Clin Trials, 2010 Apr 16; 7(5). PMID: 20392785    Free PMC article.
Bayesian adaptive randomization designs for targeted agent development.
J Jack Lee, Xuemin Gu, Suyu Liu.
Clin Trials, 2010 Jun 24; 7(5). PMID: 20571130    Free PMC article.
A Bayesian adaptive design with biomarkers for targeted therapies.
Jens C Eickhoff, KyungMann Kim, +2 authors, Jason R Gee.
Clin Trials, 2010 Jun 24; 7(5). PMID: 20571131    Free PMC article.
Methodological and practical challenges for personalized cancer therapies.
Ignacio I Wistuba, Juri G Gelovani, +2 authors, Roy S Herbst.
Nat Rev Clin Oncol, 2011 Mar 03; 8(3). PMID: 21364686
All-comers versus enrichment design strategy in phase II trials.
Sumithra J Mandrekar, Daniel J Sargent.
J Thorac Oncol, 2011 May 03; 6(4). PMID: 21532916    Free PMC article.
Statistical issues in the use of dynamic allocation methods for balancing baseline covariates.
G R Pond.
Br J Cancer, 2011 May 05; 104(11). PMID: 21540857    Free PMC article.
A "SMART" design for building individualized treatment sequences.
H Lei, I Nahum-Shani, +2 authors, S A Murphy.
Annu Rev Clin Psychol, 2012 Jan 10; 8. PMID: 22224838    Free PMC article.
Highly Cited. Review.
Design of clinical trials for biomarker research in oncology.
Sumithra J Mandrekar, Daniel J Sargent.
Clin Investig (Lond), 2012 Mar 06; 1(12). PMID: 22389760    Free PMC article.
Clinical trial designs for testing biomarker-based personalized therapies.
Tze Leung Lai, Philip W Lavori, Mei-Chiung I Shih, Branimir I Sikic.
Clin Trials, 2012 Mar 09; 9(2). PMID: 22397801    Free PMC article.
Development and use of integral assays in clinical trials.
Richard L Schilsky, James H Doroshow, Michael Leblanc, Barbara A Conley.
Clin Cancer Res, 2012 Mar 17; 18(6). PMID: 22422406    Free PMC article.
The BATTLE trial: personalizing therapy for lung cancer.
Edward S Kim, Roy S Herbst, +21 authors, Waun K Hong.
Cancer Discov, 2012 May 16; 1(1). PMID: 22586319    Free PMC article.
Highly Cited.
Bayesian clinical trials in action.
J Jack Lee, Caleb T Chu.
Stat Med, 2012 Jun 20; 31(25). PMID: 22711340    Free PMC article.
Worth adapting? Revisiting the usefulness of outcome-adaptive randomization.
J Jack Lee, Nan Chen, Guosheng Yin.
Clin Cancer Res, 2012 Jul 04; 18(17). PMID: 22753588    Free PMC article.
Study designs and statistical analyses for biomarker research.
Masahiko Gosho, Kengo Nagashima, Yasunori Sato.
Sensors (Basel), 2012 Sep 27; 12(7). PMID: 23012528    Free PMC article.
From targets to targeted therapies and molecular profiling in non-small cell lung carcinoma.
A Thomas, A Rajan, +2 authors, G Giaccone.
Ann Oncol, 2012 Nov 08; 24(3). PMID: 23131389    Free PMC article.
A review of phase II trial designs for initial marker validation.
Sumithra J Mandrekar, Ming-Wen An, Daniel J Sargent.
Contemp Clin Trials, 2013 May 15; 36(2). PMID: 23665336    Free PMC article.
Adaptive adjustment of the randomization ratio using historical control data.
Brian P Hobbs, Bradley P Carlin, Daniel J Sargent.
Clin Trials, 2013 May 22; 10(3). PMID: 23690095    Free PMC article.
Bayesian two-step Lasso strategy for biomarker selection in personalized medicine development for time-to-event endpoints.
Xuemin Gu, Guosheng Yin, J Jack Lee.
Contemp Clin Trials, 2013 Oct 01; 36(2). PMID: 24075829    Free PMC article.
Evaluating many treatments and biomarkers in oncology: a new design.
Richard Kaplan, Timothy Maughan, +4 authors, Mahesh Parmar.
J Clin Oncol, 2013 Nov 20; 31(36). PMID: 24248692    Free PMC article.
Sequential Analysis of the Cox Model under Response Dependent Allocation.
Xiaolong Luo, Gongjun Xu, Zhiliang Ying.
Stat Sin, 2013 Dec 07; 23. PMID: 24307816    Free PMC article.
Adaptive designs for clinical trials assessing biomarker-guided treatment strategies.
J Wason, A Marshall, +2 authors, N Stallard.
Br J Cancer, 2014 Mar 29; 110(8). PMID: 24667651    Free PMC article.
Exploring the statistical and clinical impact of two interim analyses on the Phase II design with option for direct assignment.
Ming-Wen An, Sumithra J Mandrekar, Martin J Edelman, Daniel J Sargent.
Contemp Clin Trials, 2014 Apr 29; 38(2). PMID: 24768938    Free PMC article.
The use of Bayesian hierarchical models for adaptive randomization in biomarker-driven phase II studies.
William T Barry, Charles M Perou, +2 authors, Joseph G Ibrahim.
J Biopharm Stat, 2014 May 20; 25(1). PMID: 24836519    Free PMC article.
Drug designs fulfilling the requirements of clinical trials aiming at personalizing medicine.
Sumithra J Mandrekar, Daniel J Sargent.
Chin Clin Oncol, 2014 Nov 22; 3(2). PMID: 25414851    Free PMC article.
Adaptive randomized phase II design for biomarker threshold selection and independent evaluation.
Lindsay A Renfro, Christina M Coughlin, Axel M Grothey, Daniel J Sargent.
Chin Clin Oncol, 2014 Dec 09; 3(1). PMID: 25485277    Free PMC article.
Statistical considerations and endpoints for clinical lung cancer studies: Can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer?
Lothar R Pilz, Christian Manegold, Gerald Schmid-Bindert.
Transl Lung Cancer Res, 2012 Mar 01; 1(1). PMID: 25806152    Free PMC article.
Adaptive clinical trial designs in oncology.
Yong Zang, J Jack Lee.
Chin Clin Oncol, 2015 Mar 27; 3(4). PMID: 25811018    Free PMC article.
Advances in Statistical Approaches Oncology Drug Development.
Anastasia Ivanova, Gary L Rosner, +3 authors, Yanping Wang.
Ther Innov Regul Sci, 2014 Jan 01; 48(1). PMID: 25949927    Free PMC article.
Adaptive design of confirmatory trials: Advances and challenges.
Tze Leung Lai, Philip W Lavori, Ka Wai Tsang.
Contemp Clin Trials, 2015 Jun 17; 45(Pt A). PMID: 26079372    Free PMC article.
A Unified Family of Covariate-Adjusted Response-Adaptive Designs Based on Efficiency and Ethics.
Jianhua Hu, Hongjian Zhu, Feifang Hu.
J Am Stat Assoc, 2015 Jun 30; 110(509). PMID: 26120220    Free PMC article.
Innovative Clinical Trial Designs: Toward a 21st-Century Health Care System.
Tze L Lai, Philip W Lavori.
Stat Biosci, 2011 Dec 01; 3(2). PMID: 26140056    Free PMC article.
Methods for identification and confirmation of targeted subgroups in clinical trials: A systematic review.
Thomas Ondra, Alex Dmitrienko, +4 authors, Martin Posch.
J Biopharm Stat, 2015 Sep 18; 26(1). PMID: 26378339    Free PMC article.
Systematic Review.
Clinical trial designs incorporating predictive biomarkers.
Lindsay A Renfro, Himel Mallick, +2 authors, Sumithra J Mandrekar.
Cancer Treat Rev, 2016 Feb 02; 43. PMID: 26827695    Free PMC article.
Biomarker-Guided Adaptive Trial Designs in Phase II and Phase III: A Methodological Review.
Miranta Antoniou, Andrea L Jorgensen, Ruwanthi Kolamunnage-Dona.
PLoS One, 2016 Feb 26; 11(2). PMID: 26910238    Free PMC article.
Precision oncology: A new era of cancer clinical trials.
Lindsay A Renfro, Ming-Wen An, Sumithra J Mandrekar.
Cancer Lett, 2016 Mar 19; 387. PMID: 26987624    Free PMC article.
MIDAS: a practical Bayesian design for platform trials with molecularly targeted agents.
Ying Yuan, Beibei Guo, +2 authors, Amir Jazaeri.
Stat Med, 2016 Apr 27; 35(22). PMID: 27112322    Free PMC article.
The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer.
Vassiliki Papadimitrakopoulou, J Jack Lee, +25 authors, Roy S Herbst.
J Clin Oncol, 2016 Aug 03; 34(30). PMID: 27480147    Free PMC article.
Highly Cited.
A Bayesian comparative effectiveness trial in action: developing a platform for multisite study adaptive randomization.
Alexandra R Brown, Byron J Gajewski, +9 authors, Richard J Barohn.
Trials, 2016 Sep 01; 17(1). PMID: 27577191    Free PMC article.
Bayesian Two-stage Biomarker-based Adaptive Design for Targeted Therapy Development.
Xuemin Gu, Nan Chen, +4 authors, J Jack Lee.
Stat Biosci, 2016 Sep 13; 8(1). PMID: 27617040    Free PMC article.
A response-adaptive design of initial therapy for emergency department patients with heart failure.
Sijin Wen, Jing Ning, Sean Collins, Donald Berry.
Contemp Clin Trials, 2016 Nov 14; 52. PMID: 27838474    Free PMC article.
Going into BATTLE: umbrella and basket clinical trials to accelerate the study of biomarker-based therapies.
Sawsan Rashdan, David E Gerber.
Ann Transl Med, 2017 Feb 06; 4(24). PMID: 28149890    Free PMC article.
Statistical controversies in clinical research: basket trials, umbrella trials, and other master protocols: a review and examples.
L A Renfro, D J Sargent.
Ann Oncol, 2017 Feb 09; 28(1). PMID: 28177494    Free PMC article.
Highly Cited. Review.
Using Bayesian modeling in frequentist adaptive enrichment designs.
Noah Simon, Richard Simon.
Biostatistics, 2017 May 19; 19(1). PMID: 28520893    Free PMC article.
Adaptive Clinical Trials: Overview of Early-Phase Designs and Challenges.
Olga Marchenko, Valerii Fedorov, +2 authors, José Pinheiro.
Ther Innov Regul Sci, 2014 Jan 01; 48(1). PMID: 28670507    Free PMC article.
A nonparametric Bayesian basket trial design.
Yanxun Xu, Peter Müller, Apostolia M Tsimberidou, Donald Berry.
Biom J, 2018 May 29; 61(5). PMID: 29808479    Free PMC article.
Master protocol trials in oncology: Review and new trial designs.
Akihiro Hirakawa, Junichi Asano, Hiroyuki Sato, Satoshi Teramukai.
Contemp Clin Trials Commun, 2018 Sep 06; 12. PMID: 30182068    Free PMC article.
Bayesian clinical trials at The University of Texas MD Anderson Cancer Center: An update.
Rebecca S Slack Tidwell, S Andrew Peng, +3 authors, J Jack Lee.
Clin Trials, 2019 Aug 28; 16(6). PMID: 31450957    Free PMC article.
Bayesian hierarchical classification and information sharing for clinical trials with subgroups and binary outcomes.
Nan Chen, J Jack Lee.
Biom J, 2018 Dec 07; 61(5). PMID: 30506747    Free PMC article.
Identifying latent subgroups of children with developmental delay using Bayesian sequential updating and Dirichlet process mixture modelling.
Patricia Gilholm, Kerrie Mengersen, Helen Thompson.
PLoS One, 2020 Jun 03; 15(6). PMID: 32484833    Free PMC article.
Early-Phase Platform Trials: A New Paradigm for Dose Finding and Treatment Screening in the Era of Precision Oncology.
Mei-Yin C Polley, Ying Kuen Cheung.
JCO Precis Oncol, 2020 Sep 15; 3. PMID: 32923846    Free PMC article.
Biomarker-Driven Oncology Clinical Trials: Key Design Elements, Types, Features, and Practical Considerations.
Chen Hu, James J Dignam.
JCO Precis Oncol, 2020 Sep 15; 3. PMID: 32923854    Free PMC article.
Bayesian Adaptive Randomization and Trial Monitoring with Predictive Probability for Time-to-event Endpoint.
Guosheng Yin, Nan Chen, J Jack Lee.
Stat Biosci, 2018 Dec 19; 10(2). PMID: 30559900    Free PMC article.
Adding flexibility to clinical trial designs: an example-based guide to the practical use of adaptive designs.
Thomas Burnett, Pavel Mozgunov, +3 authors, Thomas Jaki.
BMC Med, 2020 Nov 20; 18(1). PMID: 33208155    Free PMC article.
Group sequential designs for developing and testing biomarker-guided personalized therapies in comparative effectiveness research.
Tze Leung Lai, Olivia Yueh-Wen Liao, Dong Woo Kim.
Contemp Clin Trials, 2013 Sep 03; 36(2). PMID: 23994669    Free PMC article.
A multi-source adaptive platform design for testing sequential combinatorial therapeutic strategies.
Alexander M Kaizer, Brian P Hobbs, Joseph S Koopmeiners.
Biometrics, 2018 Jan 24; 74(3). PMID: 29359450    Free PMC article.
Recent advances in understanding amyotrophic lateral sclerosis and emerging therapies.
Lauren M Gittings, Rita Sattler.
Fac Rev, 2021 Mar 05; 9. PMID: 33659944    Free PMC article.